IL301466A - Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation - Google Patents
Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatationInfo
- Publication number
- IL301466A IL301466A IL301466A IL30146623A IL301466A IL 301466 A IL301466 A IL 301466A IL 301466 A IL301466 A IL 301466A IL 30146623 A IL30146623 A IL 30146623A IL 301466 A IL301466 A IL 301466A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- hht
- subject
- treatment
- telangiectasia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| PCT/EP2021/076811 WO2022069552A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301466A true IL301466A (en) | 2023-05-01 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301466A IL301466A (en) | 2020-09-30 | 2021-09-29 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (https=) |
| EP (1) | EP4221713A1 (https=) |
| JP (1) | JP2023543993A (https=) |
| KR (1) | KR20230080448A (https=) |
| CN (1) | CN116419924A (https=) |
| AU (1) | AU2021352108B2 (https=) |
| BR (1) | BR112023004885A2 (https=) |
| CA (1) | CA3192433A1 (https=) |
| CL (1) | CL2023000926A1 (https=) |
| GB (1) | GB2600384A (https=) |
| IL (1) | IL301466A (https=) |
| MX (1) | MX2023002996A (https=) |
| WO (1) | WO2022069552A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7910561B2 (en) | 2004-12-15 | 2011-03-22 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| EP1898903B8 (en) | 2005-06-10 | 2013-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2008011032A1 (en) | 2006-07-17 | 2008-01-24 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| JP2010512312A (ja) | 2006-12-06 | 2010-04-22 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522048A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｋｔ活性の阻害剤 |
| US8536193B2 (en) | 2008-06-03 | 2013-09-17 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| EA201101186A1 (ru) | 2009-02-13 | 2012-04-30 | Байер Фарма Акциенгезельшафт | Конденсированные пиримидины |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as akt kinase inhibitors |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| MX2020002611A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Activador especifico de akt3 y usos del mismo. |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 JP JP2023519016A patent/JP2023543993A/ja active Pending
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240092801A1 (en) | 2024-03-21 |
| AU2021352108A1 (en) | 2023-05-11 |
| CN116419924A (zh) | 2023-07-11 |
| GB2600384A (en) | 2022-05-04 |
| WO2022069552A1 (en) | 2022-04-07 |
| CL2023000926A1 (es) | 2023-11-03 |
| EP4221713A1 (en) | 2023-08-09 |
| JP2023543993A (ja) | 2023-10-19 |
| MX2023002996A (es) | 2023-05-03 |
| KR20230080448A (ko) | 2023-06-07 |
| CA3192433A1 (en) | 2022-04-07 |
| GB202015536D0 (en) | 2020-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| US12466839B2 (en) | 2025-11-11 |
| BR112023004885A2 (pt) | 2023-04-18 |
| AU2021352108A9 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2935248B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| CA3052625A1 (en) | Compositions and methods for treating heart failure | |
| JP2007502300A (ja) | Ｇｓｋ−３インヒビターおよびその使用 | |
| AU2021352108B2 (en) | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | |
| TW201016671A (en) | Novel imidazolidine compounds as androgen receptor modulators | |
| EP3700891A1 (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
| JP6587637B2 (ja) | カルボキサミド誘導体 | |
| AU2017281980B2 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| CN110325523B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| JP7713972B2 (ja) | 線維性疾患治療用医薬組成物 | |
| KR20120134605A (ko) | 1，2，3，4，6?펜타?오?갈로일?베타?디?글루코오스및 이마티니브를 유효성분으로 포함하는 만성 골수성 백혈병 치료용 조성물 | |
| WO2017157992A1 (en) | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders | |
| EP4182311B1 (en) | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | |
| EA049324B1 (ru) | Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии | |
| RU2791639C2 (ru) | Средство, увеличивающее мозговой кровоток | |
| HK40074977A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40074982A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| WO2001001981A1 (fr) | Antagonistes de recepteur de vegf | |
| HK40074980A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40035558A (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
| HK40011855B (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40011855A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK1213877B (en) | Compounds and methods for kinase modulation, and indications therefor |